SCHEMBL361530

SCHEMBL361530

COCCOCCOS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
LMNA P02545 1/20 0.46
HPGD P15428 1/20 0.46
HTT P42858 1/20 0.46
CA12 O43570 2/20 0.45
CA1 P00915 2/20 0.45
CA9 Q16790 2/20 0.45
GAA P10253 1/20 0.41
STAT3 P40763 1/20 0.40
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
MAPT P10636 1/20 0.39
PSMD10 O75832 1/20 0.39
CA2 P00918 1/20 0.38
CA3 P07451 1/20 0.38
CA6 P23280 1/20 0.38
CA5A P35218 1/20 0.38
CA7 P43166 1/20 0.38
CA5B Q9Y2D0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19003422 1.00 ALDH1A1 (0.47) ALDH1A1LMNAHPGDHTTCA12
SCHEMBL18998977 1.00 ALDH1A1 (0.47) ALDH1A1LMNAHPGDHTTCA12
SCHEMBL2329512 1.00 ALDH1A1 (0.47) ALDH1A1LMNAHPGDHTTCA12
SCHEMBL1218220 1.00 ALDH1A1 (0.47) ALDH1A1LMNAHPGDHTTCA12
SCHEMBL40774 1.00 ALDH1A1 (0.47) ALDH1A1LMNAHPGDHTTCA12
SCHEMBL25398474 1.00 ALDH1A1 (0.47) ALDH1A1LMNAHPGDHTTCA12
SCHEMBL8282614 1.00 ALDH1A1 (0.47) ALDH1A1LMNAHPGDHTTCA12
SCHEMBL22262524 1.00 ALDH1A1 (0.47) ALDH1A1LMNAHPGDHTTCA12
SCHEMBL21877144 1.00 ALDH1A1 (0.47) ALDH1A1LMNAHPGDHTTCA12
SCHEMBL13169282 1.00 ALDH1A1 (0.47) ALDH1A1LMNAHPGDHTTCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 381 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230000983-A1 METHODS AND COMPOSITIONS FOR SYNTHESIS OF TWO-PHOTON CLEAVABLE PHOSPHORAMIDITE MOLECULES FOR OLIGONUCLEOTIDE CONJUGATION CITY UNIVERSITY OF HONG KONG (HK) 2023-01-05 US claimed
CN-108299498-B Quaternary phosphonium salt with p-toluenesulfonate as anion and synthesis method, preparation method and application thereof 暨南大学 2020-06-16 CN claimed
CN-101831054-B Method for distinguishing fungi and bacteria CHINESE ACAD INST CHEMISTRY 2011-11-16 CN claimed
CN-101831054-A Method for distinguishing fungi and bacteria CHINESE ACAD INST CHEMISTRY 2010-09-15 CN claimed
US-20250313572-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC (US) 2025-10-09 US disclosed
US-12435060-B2 Acylamino bridged heterocyclic compound, and composition and application thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2025-10-07 US disclosed
US-20250019351-A1 COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2025-01-16 US disclosed
US-20240360088-A1 WATER-SOLUBLE NERVE DYES FOR IN VIVO NERVE-SPECIFIC IMAGING OREGON HEALTH & SCIENCE UNIVERSITY (US) 2024-10-31 US disclosed
US-12077512-B2 Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2024-09-03 US disclosed
US-20240228509-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC (US) 2024-07-11 US disclosed
EP-4367104-A1 WATER-SOLUBLE NERVE DYES FOR IN VIVO NERVE-SPECIFIC IMAGING Oregon Health & Science University (US) 2024-05-15 EP disclosed
US-20240139164-A1 RAPAMYCIN ANALOGS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2024-05-02 US disclosed
EP-0349748-A1 Substituted N-aryl-nitrogen containing heterocycles BAYER AG (DE) 1990-01-10 EP disclosed
EP-0146269-B1 HETERO-POLYCYCLIC AROMATIC COMPOUND IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1990-01-03 EP disclosed
US-4719296-A PHOTOCHROMISM MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) 1988-01-12 US disclosed
US-4650882-A Dyes having two 5-membered lactone rings fused to a central cyclohexa-1.4-diene nucleus IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1987-03-17 US disclosed
EP-0146269-A2 Hetero-polycyclic aromatic compound IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1985-06-26 EP disclosed
US-4436664-A PHASE TRANSFER AGENTS W. R. GRACE & CO. (US) 1984-03-13 US disclosed
US-4018832-A Novel complexing agents derived from cyclotriveratrylene EASTMAN KODAK COMPANY (US) 1977-04-19 US disclosed
US-4001279-A CARRY INSOLUBLE REAGENT SUBSTANCES INTO SOLUTION IN NON-HYDROXYLIC MEDIA; CROWN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1977-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228509-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE MCL1, BCL2A1, BCL2L10 ALDH1A1 641/4885LMNA 420/4885HPGD 4461/4885
US-20240139164-A1 RAPAMYCIN ANALOGS AND USES THEREOF RICTOR, MTOR, RPTOR ALDH1A1 4627/4885LMNA 3835/4885HPGD 3013/4885
US-20230000983-A1 METHODS AND COMPOSITIONS FOR SYNTHESIS OF TWO-PHOTON CLEAVABLE PHOSPHORAMIDITE MOLECULES FOR OLIGONUCLEOTIDE CONJUGATION PCNA, POLB, NCL ALDH1A1 4749/4885LMNA 553/4885HPGD 3818/4885
US-20250313572-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE MCL1, BCL2A1, BCL2L10 ALDH1A1 641/4885LMNA 420/4885HPGD 4461/4885
US-12077512-B2 Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment GABBR1, GABBR2, PMP22 ALDH1A1 2517/4885LMNA 3058/4885HPGD 3913/4885
US-20240360088-A1 WATER-SOLUBLE NERVE DYES FOR IN VIVO NERVE-SPECIFIC IMAGING PAX8, GAP43, PAX2 ALDH1A1 1457/4885LMNA 1129/4885HPGD 1476/4885
US-20250019351-A1 COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT GABBR1, GABBR2, PMP22 ALDH1A1 2517/4885LMNA 3058/4885HPGD 3913/4885
US-12435060-B2 Acylamino bridged heterocyclic compound, and composition and application thereof RIPK1, RIPK3, RIPK4 ALDH1A1 4164/4885LMNA 2659/4885HPGD 2673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.